Dear Editor:

The calcineurin-inhibitor tacrolimus (FK506) is widely used to prevent rejection and graft loss in solid organ transplantation. It induces immunosuppression by inhibiting interleukin 2 and interferon-gamma production. Tacrolimus is metabolized in the liver via CYP3A4 and has high inter-and intra-personal variability [1]. Moreover, tacrolimus has a very narrow therapeutic index, requiring constant increase for success of solid organ transplantation while reducing its adverse effects. Therefore, monitoring tacrolimus blood trough concentration is mandatory to optimize treatment after organ transplantation. The most common side effects of tacrolimus are neurotoxicity, nephrotoxicity, and electrolyte abnormalities. Neurologic complications occur in 8.2% of patients who have undergone liver transplantation, with encephalopathy being the most common. Herein, we report for the first time an infant who underwent living donor liver transplantation (LDLT) and developed chorea due to tacrolimus neurotoxicity. Written informed consent was obtained from the patient’s parents.

A 45-day-old boy presented with biliary atresia, for which he underwent a Kasai portoenterostomy at 80 days of age. Biliary drainage was achieved, but his course was complicated by recurrent cholangitis episodes and ascites. He was not thriving and developed portal vein thrombosis. Therefore, LDLT was planned. At 10 months of age, weighing 6 kg, LDLT was performed with a liver from his father. A reduced left lateral segment graft weighing 180 g was implanted following thrombectomy and portal vein reconstruction with patch venoplasty. The graft weight-to-body weight ratio was 3%. Postoperative anti-rejection therapy initially consisted of corticosteroid and tacrolimus. Tacrolimus was adjusted to maintain trough blood level within the range of 10–12 ng/ml. The targeted tacrolimus level was between 5–6 ng/ml. On post-transplant day 5, mycophenolate mofetil (MMF) was added.

The early postoperative course was uneventful except for atelectasis. On postoperative day 6, the patient developed choreiform movements, which were non-repetitive, irregularly timed, spontaneous movements in both arms. No obvious reason for these movements could be found. He was on methylprednisolone (0.3 mg/kg/day), tacrolimus (0.125 mg/kg/day), and MMF (530 mg/m²/day). The tacrolimus blood trough level was 16.1 ng/ml. After starting MMF, the tacrolimus blood level target was decreased from 10–12 ng/ml to 5–6 ng/ml. However, during follow-up, the blood drug level started to increase. The tacrolimus dose, which was started at 0.25 mg/day, was continued at 0.5 mg in the morning and evening according

---

**Letter to the Editor**

Received: October 5, 2021  
Revised: April 8, 2022  
Accepted: April 18, 2022

**Corresponding author**  
Fevzi Kahveci  
Department of Pediatrics, Division of Critical Care Medicine, Ankara University School of Medicine, Ankara, Türkiye  
Tel: +90-532-0631836  
Fax: +90-312-3623441  
E-mail: fevziikahvecii@gmail.com

---

Copyright © 2022 The Korean Society of Critical Care Medicine  
This is an Open Access article distributed under the terms of Creative Attritions Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

---

https://www.accjournal.org
mechanism for its action is suppression of calcineurin activity. Tacrolimus currently is a standard immunosuppressant. Risk factors for tacrolimus neurotoxicity are encephalopathy, seizure, and low magnesium level. Vasospasm resulting in brain hypoperfusion was demonstrated in tacrolimus users by magnetic resonance angiography. That study indicated that tacrolimus can cause PRES via reversible vasospasm resulting in brain hypoperfusion [3]. Furthermore, tacrolimus can induce encephalopathy by hypomagnesemia, which can lead to vasoconstriction. Thus, in our patient, chorea, seizure, and encephalopathy occurred due to low magnesium level.

To the best of our knowledge, there is only one case report describing chorea in a 14-year-old girl who was given tacrolimus following renal transplantation. However, blood tacrolimus trough level at the time of chorea was not included in that case report [4]. The authors report that the chorea symptoms resolved by maintaining a tacrolimus blood trough concentration at 4–5 ng/ml [4]. Similarly, in our patient, choreiform movements regressed when tacrolimus blood trough level decreased. If tacrolimus neurotoxicity occurs, the first step is to reduce or skip the dosage. Phenytoin, which is a strong CYP3A4/5 inducer, can be used to increase the metabolism of tacrolimus to combat neurotoxicity. Hemodialysis is not useful in tacrolimus toxicity since tacrolimus is lipophilic and mostly bound to plasma proteins and erythrocytes. Tacrolimus has a high distribution volume and its blood concentration is 10 to 30 times higher than plasma concentration. Therefore, red blood cell exchange is the only reliable option to address tacrolimus toxicity [5].

In conclusion, neurotoxicity is a serious adverse effect of tacrolimus, and the precise mechanism of action is not understood. To prevent adverse effects, electrolyte disturbances and blood trough levels above the therapeutic range should be avoided, especially in infants receiving tacrolimus.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.
Tacrolimus toxicity-related chorea

ORCID

Fevzi Kahveci https://orcid.org/0000-0002-5176-1040
Tanıl Kendirli https://orcid.org/0000-0001-9458-2803
Anar Gurbanov https://orcid.org/0000-0003-1383-5130
Edin Botan https://orcid.org/0000-0003-4586-1595
Meltem Koloğlu https://orcid.org/0000-0001-7726-7633
Ömer Bektaş https://orcid.org/0000-0002-2514-8461
Zarife Kuloglu https://orcid.org/0000-0001-9442-7790
Deniz Balci https://orcid.org/0000-0002-6246-1123
Aydan Kansu https://orcid.org/0000-0002-3133-9846

AUTHOR CONTRIBUTIONS

Conceptualization: FK, AG, EB. Data curation: AG, OB. Formal analysis: FK. Methodology: TK, MK, ZK, DB. Project administration: FK, TK, ZK. Visualization: FK. Writing—original draft: FK, AG, EB, MK, DB, AK. Writing—review & editing: TK, EB, MK, OB, ZK, DB, AK.

REFERENCES

1. Op den Buijsch RA, Christiaans MH, Stolk LM, Vries JE, Cheung CY, Undre NA, et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007;21:427-35.
2. Dawson TM. Immunosuppressants, immunophilins, and the nervous system. Ann Neurol 1996;40:559-60.
3. Bartynski WS, Boardman JF. Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2008;29:447-55.
4. Mroué A, Azar H. Improvement of a post pump chorea after switching to a low dose tacrolimus regimen in a kidney transplant recipient: a case report. J Urol Ren Dis 2018;198.
5. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623-53.